944 results match your criteria Pruritus and Systemic Disease


The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients.

Medicina (Kaunas) 2021 May 22;57(6). Epub 2021 May 22.

Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.

: Atopic dermatitis (AD) is a disease with a complex pathophysiology involving immune-mediated reactions that lead to skin lesions that are typically localized and recurrent. Following the outbreak of the COVID-19 (coronavirus disease 2019) pandemic, attempting to assess the impact of SARS-CoV-2 infection on diseases caused by complex immune mechanisms has become important. The aim of this study was to assess the impact of SARS-CoV-2 infection on the course of AD, including immunosuppressive therapy, in patients with a severe form of the disease. Read More

View Article and Full-Text PDF

Float like a Butterfly, Sting like One Too.

Pediatr Dermatol 2021 May 31. Epub 2021 May 31.

Department of Dermatology, University of Vermont Medical Center, Burlington, VT, USA.

Rash after contact with butterflies has not been previously reported in the medical literature to our knowledge. We describe potentially the first suspected case of a cutaneous reaction to the Compton tortoiseshell butterfly (Nymphalis vaualbum) in a young boy who developed urticaria after the modified hairs of the butterfly embedded within his finger. His urticaria improved through treatment with oral and topical steroids as well as systemic antihistamines. Read More

View Article and Full-Text PDF

Approach to the Patient with Chronic Pruritus.

Med Clin North Am 2021 Jul;105(4):699-721

Dr Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, University of Miami Hospital, 1600 Northwest 10th Avenue RMSB Building, 10th Street, 2067B Miami, FL, USA. Electronic address:

Chronic pruritus (itch lasting ≥6 weeks) is a bothersome chief complaint that may present in a broad variety of diseases. Most itch-causing diagnoses fit into 1 of 5 categories (inflammatory, secondary to systemic disease, neuropathic, chronic pruritus of undetermined origin, and psychogenic itch) and this broad differential can be narrowed using key findings in the history and physical. In this article, we discuss which key findings are most pertinent for narrowing this differential and guiding further workup and treatment, as well as how to treat many itchy conditions. Read More

View Article and Full-Text PDF

Health-related quality of life and economic burden of prurigo nodularis.

J Am Acad Dermatol 2021 May 28. Epub 2021 May 28.

Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD,; Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD. Electronic address:

Background: Prurigo nodularis (PN) is an understudied, pruritic inflammatory skin disease. Little is known about the effect of PN on quality of life (QoL) and its associated economic burden.

Objective: To quantify QoL impact and economic implications of PN. Read More

View Article and Full-Text PDF

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet 2021 Jun 21;397(10290):2169-2181. Epub 2021 May 21.

Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Background: Systemic therapies are typically combined with topical corticosteroids for the management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis. We aimed to assess the efficacy and safety of upadacitinib plus topical corticosteroids compared with placebo for the treatment of moderate-to-severe atopic dermatitis. Read More

View Article and Full-Text PDF

Experimental Drugs with the Potential to Treat Atopic Eczema.

J Exp Pharmacol 2021 12;13:487-498. Epub 2021 May 12.

Department of Pediatrics, The University of Calgary, and the Alberta Children's Hospital, Calgary, Alberta, Canada.

Introduction: Eczema or atopic dermatitis (AD) is a chronically relapsing dermatosis characterized by pruritus and a significant impact on the quality of life.

Methods: The authors undertook a structured search of peer-reviewed research articles from PubMed and Google Scholar. Recent and up-to-date studies relevant to the topic were included. Read More

View Article and Full-Text PDF

Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.

Lupus 2021 May 18:9612033211016098. Epub 2021 May 18.

Department of Dermatology, University of Rzeszow, Rzeszow, Poland.

Objective: Pruritus is an important symptom frequently accompanying various inflammatory skin conditions and some recent data indicated that it may be associated with autoimmune connective tissue diseases. The aim of this study was to assess the frequency and clinical presentation of itch in CLE.

Methods: A multinational, prospective, cross-sectional study was performed to assess the prevalence, intensity and clinical characteristic of pruritus in various subtypes of CLE. Read More

View Article and Full-Text PDF

Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus.

Front Med (Lausanne) 2021 14;8:641163. Epub 2021 Apr 14.

Department of Medicine 1, University Hospital Erlangen and Translational Research Center, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Chronic pruritus affects up to 70% of patients with immune-mediated hepatobiliary disorders. Antagonists of the μ-opioid receptor (MOR) and agonists of the κ-opioid receptor (KOR) are used to treat hepatic itch, albeit with limited success. An imbalance between ligands of MOR and KOR receptors has recently been suggested as a potential mechanism of hepatic pruritus. Read More

View Article and Full-Text PDF

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.

Lancet 2021 Apr;397(10284):1564-1575

Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background: Sonelokimab (also known as M1095) is a novel trivalent nanobody comprised of monovalent camelid-derived (ie, from the Camelidae family of mammals, such as camels, llamas, and alpacas) nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin. Nanobodies are a novel class of proprietary therapeutic proteins based on single-domain, camelid, heavy-chain-only antibodies. We assessed the efficacy, safety, and tolerability of sonelokimab across four dosage regimens compared with placebo in patients with plaque-type psoriasis. Read More

View Article and Full-Text PDF

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.

Expert Opin Drug Discov 2021 May 5:1-16. Epub 2021 May 5.

SC Di Gastroenterologia Ed Epatologia, Azienda Ospedaliera Di Perugia, Perugia, Italy.

Introduction: The farnesoid-x-receptor (FXR) is a ubiquitously expressed nuclear receptor selectively activated by primary bile acids.

Area Covered: FXR is a validated pharmacological target. Herein, the authors review preclinical and clinical data supporting the development of FXR agonists in the treatment of nonalcoholic fatty liver disease. Read More

View Article and Full-Text PDF

Pruritus in autoimmune connective tissue diseases.

Authors:
Hee Joo Kim

Ann Transl Med 2021 Mar;9(5):441

Department of Dermatology, Gachon Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.

Pruritus is one of the most common and bothersome symptoms of skin disorders, and its clinical characteristics and related pathomechanisms have been well described in certain dermatologic conditions, such as atopic dermatitis and urticaria. Although pruritus is believed to be as common in cutaneous autoimmune connective tissue diseases (ACTDs) as in other inflammatory skin disorders, its true characteristics have not been elucidated either qualitatively or quantitatively. Pruritus is present in ACTDs with various prevalence rates, characteristics, and mechanisms depending on the disease types. Read More

View Article and Full-Text PDF

Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.

Front Immunol 2021 25;12:569287. Epub 2021 Mar 25.

Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.

Bullous pemphigoid (BP) is a prototypic autoimmune disorder of the elderly, characterized by serum IgG autoantibodies, namely anti-BP180 and anti-BP230, directed against components of the basal membrane zone that lead to sub-epidermal loss of adhesion. Pruritus may be indicative of a pre-clinical stage of BP, since a subset of these patients shows serum IgG autoantibodies against BP230 and/or BP180 while chronic pruritus is increasingly common in the elderly population and is associated with a variety of dermatoses. Clinical and experimental evidence further suggests that pruritus of the elderly may be linked to autoimmunity with loss of self-tolerance against cutaneous autoantigens. Read More

View Article and Full-Text PDF

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report.

Medicine (Baltimore) 2021 Apr;100(14):e25352

Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Dermatology Clinic, Sibiu, Romania.

Rationale: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Read More

View Article and Full-Text PDF

Effect of intranasal corticosteroid treatment on allergen-induced changes in group 2 innate lymphoid cells in allergic rhinitis with mild asthma.

Allergy 2021 Mar 30. Epub 2021 Mar 30.

Department of Medicine, McMaster University, Hamilton, ON, Canada.

Background: Allergic rhinitis is characterized by rhinorrhea, nasal congestion, sneezing and nasal pruritus. Group 2 innate lymphoid cells (ILC2s), CD4 T cells and eosinophils in nasal mucosa are increased significantly after nasal allergen challenge (NAC). Effects of intranasal corticosteroids (INCS) on ILC2s remain to be investigated. Read More

View Article and Full-Text PDF

Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA).

Pediatr Dermatol 2021 Mar 20;38(2):364-370. Epub 2021 Mar 20.

Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.

Background/objective: In spring 2020, high numbers of children presented with acral pernio-like skin rashes, concurrent with the coronavirus disease 2019 (COVID-19) pandemic. Understanding their clinical characteristics/ infection status may provide prognostic information and facilitate decisions about management.

Methods: A pediatric-specific dermatology registry was created by the Pediatric Dermatology COVID-19 Response Task Force of the Society for Pediatric Dermatology (SPD) and Pediatric Dermatology Research Alliance (PeDRA) and was managed by Children's Hospital of Philadelphia using REDCap. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.

Am J Clin Dermatol 2021 Mar 16. Epub 2021 Mar 16.

Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Via Francesco De Santis, snc., 86100, Campobasso, Italy.

Objective: The objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks.

Methods: A retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. Inclusion criteria were: age ≥ 65 years; diagnosis of atopic dermatitis made by an expert dermatologist; Eczema Area and Severity Index ≥ 24; and a contraindication, side effects, or failure to respond to cyclosporine. Read More

View Article and Full-Text PDF

Systemic mastocytosis with flushing and hypotension: A case report and literature review.

Exp Ther Med 2021 Apr 25;21(4):404. Epub 2021 Feb 25.

Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.

Systemic mastocytosis (SM) is a heterogeneous disease of the bone marrow, which is characterized by the abnormal proliferation and infiltration of mast cells in one or more organs, such as the skin, bone marrow, digestive tract, liver and spleen. Urticaria pigmentosa is a typical but infrequent manifestation of SM. Other clinical presentations are non-specific, varying from pruritus and hypotension to multiple organ dysfunction, which may be lethal when hemodynamic changes occur, such as the sharp decline in blood pressure observed in the present case. Read More

View Article and Full-Text PDF

Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions.

Front Med (Lausanne) 2021 18;8:627985. Epub 2021 Feb 18.

Division of Experimental Allergy and Immunodermatology, Faculty of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.

Pruritus is a common, but very challenging symptom with a wide diversity of underlying causes like dermatological, systemic, neurological and psychiatric diseases. In dermatology, pruritus is the most frequent symptom both in its acute and chronic form (over 6 weeks in duration). Treatment of chronic pruritus often remains challenging. Read More

View Article and Full-Text PDF
February 2021

Effects of mineral complex material treatment on 2,4- dinitrochlorobenzene-induced atopic dermatitis like-skin lesions in mice model.

BMC Complement Med Ther 2021 Mar 3;21(1):82. Epub 2021 Mar 3.

Department of Environmental Medical Biology, Wonju College of Medicine, Yonsei University, Wonju, Gangwon-do, 26426, Republic of Korea.

Background: Atopic dermatitis (AD) is a chronic allergic inflammatory skin disease characterized by complex pathogenesis including skin barrier dysfunction, immune-redox disturbances, and pruritus. Prolonged topical treatment with medications such as corticosteroids, calcineurin inhibitors, and T-cell inhibitors may have some potential side-effects. To this end, many researchers have explored numerous alternative therapies using natural products and mineral compounds with antioxidant or immunomodulatory effects to minimize toxicity and adverse-effects. Read More

View Article and Full-Text PDF

Case of cholestatic jaundice associated with papillary carcinoma of thyroid: a multidisciplinary challenge.

BMJ Case Rep 2021 Feb 5;14(2). Epub 2021 Feb 5.

Gastroenterology and Human Nutrition Unit, AIIMS, New Delhi, India

The report describes a patient with cholestatic jaundice who had incidentally detected parathyroid hormone-independent hypercalcaemia. The differential diagnosis for this presentation includes systemic granulomatous and infiltrative disorders, drug-induced liver injury and malignancy. As the initial investigations were non-contributory towards the aetiology, she was given steroids and later plasma exchange for symptomatic treatment. Read More

View Article and Full-Text PDF
February 2021

A rare manifestation of indolent systemic mastocytosis and its management during the coronavirus disease 2019 pandemic; educational lessons from Syria.

Ann Med Surg (Lond) 2021 Feb 21;62:293-297. Epub 2021 Jan 21.

Department of Pathology, Cancer Research Center at Tishreen University Hospital, Latakia, Syria.

The diagnosis of indolent systemic mastocytosis can be quite a challenge due to its wide spectrum of clinical manifestations. We are reporting a case of misdiagnosed indolent systemic mastocytosis in a 41-year-old male that has been wrongly treated first as a Non-Hodgkin lymphoma. The patient had generalized lymphadenopathy and eosinophilia, which are rare manifestations of indolent systemic mastocytosis. Read More

View Article and Full-Text PDF
February 2021

Topical Mucoadhesive Alginate-Based Hydrogel Loading Ketorolac for Pain Management after Pharmacotherapy, Ablation, or Surgical Removal in Condyloma Acuminata.

Gels 2021 Jan 23;7(1). Epub 2021 Jan 23.

Departament de Farmàcia, Tecnologia Farmacèutica i Fisicoquímica, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Condyloma acuminata is an infectious disease caused by the human papilloma virus (HPV) and one of the most common sexually transmitted infections. It is manifested as warts that frequently cause pain, pruritus, burning, and occasional bleeding. Treatment (physical, chemical, or surgical) can result in erosion, scars, or ulcers, implying inflammatory processes causing pain. Read More

View Article and Full-Text PDF
January 2021

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.

JCI Insight 2021 01 25;6(2). Epub 2021 Jan 25.

Department of Dermatology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea.

BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease that causes severe mucocutaneous fragility due to mutations in COL7A1 (encoding type VII collagen [C7]). In this phase I/IIa trial, we evaluated the safety and possible clinical efficacy of intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in patients with RDEB.METHODSFour adult and two pediatric patients with RDEB were treated with 3 intravenous injections of hUCB-MSCs (1 × 106 to 3 × 106 cells/kg) every 2 weeks and followed up for 8-24 months after treatment. Read More

View Article and Full-Text PDF
January 2021

Cutaneous Cell-Mediated Delayed Hypersensitivity to Intravitreal Bevacizumab.

Middle East Afr J Ophthalmol 2020 Jul-Sep;27(3):182-184. Epub 2020 Oct 30.

Department of Ocular Tumor, Orbital Disease and Ophthalmic Radiation Therapy., The New York Eye Cancer Center, New York, NY, USA.

The literature contains few reports describing autoimmune reactions to intravitreal bevacizumab and no Type-IV delayed hypersensitivity reactions. This was unexpected, as administration of intravenous bevacizumab has frequently caused dermatologic side-effects. This difference was likely attributable in part to the minimum 300-times difference between intravitreal versus intravenous dosing. Read More

View Article and Full-Text PDF
January 2021

Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.

Dermatol Ther 2021 03 7;34(2):e14798. Epub 2021 Feb 7.

Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain.

Guselkumab is a fully human immunoglobulin-G1-lambda (IgG1λ) monoclonal antibody that binds selectively to the p19 subunit of interleukin 23. Few series of real clinical practice that reflect the use of guselkumab have been published so far, including the measure of survival at more than 52 weeks. An observational, longitudinal, retrospective study of real clinical practice of patients with moderate to severe psoriasis receiving treatment with guselkumab 100 mg subcutaneous every 8 weeks in five tertiary hospitals in Andalusia (Spain) was carried out. Read More

View Article and Full-Text PDF

Molecular Aspects of Pruritus Pathogenesis in Psoriasis.

Int J Mol Sci 2021 Jan 16;22(2). Epub 2021 Jan 16.

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, PL-35-055 Rzeszow, Poland.

Psoriasis is a chronic, systemic inflammatory disease with a genetic background that involves almost 3% of the general population worldwide. Approximately, 70-90% of patients with psoriasis suffer from pruritus, an unpleasant sensation that provokes a desire to scratch. Despite the enormous progress in understanding the mechanisms that cause psoriasis, the pathogenesis of psoriasis-related pruritus still remains unclear. Read More

View Article and Full-Text PDF
January 2021

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.

J Dermatolog Treat 2021 Mar 18;32(2):164-173. Epub 2021 Jan 18.

Sanofi Genzyme, Cambridge, MA, USA.

Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions.

Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Read More

View Article and Full-Text PDF

Hematoporphyrin monomethyl ether-mediated photodynamic therapy temporarily relieves severe pruritis from phakomatosis pigmentovascularis: A case report.

Photodiagnosis Photodyn Ther 2021 Mar 8;33:102180. Epub 2021 Jan 8.

Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 1278 Baode Road, Shanghai, 200443, People's Republic of China. Electronic address:

Phakomatosis pigmentovascularis (PPV) is a rare congenital syndrome characterized by (a) capillary malformations, such as port-wine stain (PWS), and (b) pigmented lesions, such as pigmented trichoepidermal nevus, café-au-lait spots, and dermal melanocytosis with or without systemic damage. Severe pruritus has not previously been reported among PPV patients. Here, we report a pediatric case of PPV with severe pruritus, which was refractory to various long-term oral antiallergic agents and topical tacrolimus but was temporarily responsive to hematoporphyrin monomethyl ether-mediated photodynamic therapy (HMME-PDT). Read More

View Article and Full-Text PDF

Frontal Fibrosing Alopecia: Successfully Treated with Methotrexate or Just the Natural Disease Progression?

Acta Dermatovenerol Croat 2020 Dec;28(3):188-189

Matheo Augusto Morandi Stumpf, MD, Av. Carlos Cavalcanti, 4748, Medicine Department, Uvaranas, CEP: 84030-900, Ponta Grossa, Brazil;

A 53 year-old-woman presented to our dermatology clinic with a 3-year history of hair loss and pruritus of the anterior scalp. She denied drug use, comorbidities, and other systemic symptoms. Physical examination revealed a band-like recession of the frontotemporal hairline with loss of the eyebrows and perifollicular erythema. Read More

View Article and Full-Text PDF
December 2020